Smith & Nephew plc is a major global company operating in the Healthcare sector, with a specific focus on the Medical Devices industry. The company boasts a significant market capitalization of 9.78 Billion, solidifying its position as a key player in areas such as orthopaedics, sports medicine, and advanced wound management. Its extensive portfolio of products and established market presence make it a closely watched stock by investors in the healthcare space.

From a technical standpoint, Smith & Nephew plc currently receives a Sell rating with a total score of -2. This assessment is based on several key indicators. The long-term trend could not be determined as the 200-day moving average was unavailable. Furthermore, the ADX indicator at 13.47 suggests a very weak or non-directional market, contributing a neutral score. The RSI at 51.77 is also in neutral territory, indicating balanced momentum. However, bearish signals are present. The MACD histogram is negative, signaling a bearish crossover and building downward momentum. This is further supported by the On-Balance Volume (OBV), which is below its moving average, pointing to distribution pressure where volume is higher on down days.

In conclusion, the technical analysis points to a cautious or bearish outlook. While the fundamentals show a moderate P/E ratio of 21.52, the reported dividend yield is exceptionally high and may require further verification. The lack of recent earnings data, with the last reported EPS being unavailable and the next earnings date set far in the future on on 04/08/2026, creates uncertainty. Without a near-term positive catalyst from earnings, the negative signals from our technical indicators currently dominate the outlook, supporting the overall Sell rating.